U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H37ClO7
Molecular Weight 521.042
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BECLOMETHASONE DIPROPIONATE

SMILES

[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]3(Cl)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=KUVIULQEHSCUHY-XYWKZLDCSA-N
InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1

HIDE SMILES / InChI

Molecular Formula C28H37ClO7
Molecular Weight 521.042
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.419 ng/mL
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.985 ng × h/mL
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Disc. AE: Epistaxis, Increased intraocular pressure...
AEs leading to
discontinuation/dose reduction:
Epistaxis (5 patients)
Increased intraocular pressure (1 patient)
Colon cancer (2 patients)
Nasal septum ulceration (2 patients)
Nasal discomfort (2 patients)
Sinusitis (2 patients)
Nasal congestion (1 patient)
Headache (1 patient)
Nasal mucosal disorder (1 patient)
Sources: Page: page 114
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources: Page: page 114
Disc. AE: Sinusitis, Nasopharyngitis...
AEs leading to
discontinuation/dose reduction:
Sinusitis
Nasopharyngitis
Nasal congestion
Headache
Infection respiratory
Sources: Page: page 114
AEs

AEs

AESignificanceDosePopulation
Headache 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Increased intraocular pressure 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Nasal congestion 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Nasal mucosal disorder 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Colon cancer 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Nasal discomfort 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Nasal septum ulceration 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Sinusitis 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Epistaxis 5 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources: Page: page 114
Headache Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources: Page: page 114
Infection respiratory Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources: Page: page 114
Nasal congestion Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources: Page: page 114
Nasopharyngitis Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources: Page: page 114
Sinusitis Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources: Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources: Page: page 114
PubMed

PubMed

TitleDatePubMed
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.
1999 Apr
Differential potency of beclomethasone esters in-vitro on human T-lymphocyte cytokine production and osteoblast activity.
2000 Apr
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids.
2006 Mar
Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts.
2010 Oct 1
Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway.
2011 Dec
Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.
2013
Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes.
2013 May
Patents
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:10:44 GMT 2023
Edited
by admin
on Fri Dec 15 15:10:44 GMT 2023
Record UNII
5B307S63B2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BECLOMETHASONE DIPROPIONATE
MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
TOPSTER
Brand Name English
PROPADERM FORTE
Common Name English
NSC-755901
Code English
SCH 8020W
Code English
QNASL
Common Name English
INALONE R
Common Name English
BECLOMETASONE DIPROPIONATE, ANHYDROUS [EP IMPURITY]
Common Name English
SGX-203
Code English
BECLOMETASONE DIPROPIONATE [JAN]
Common Name English
QVAR
Brand Name English
BECLOMETASONE DIPROPIONATE
WHO-DD   WHO-IP  
Common Name English
BECLOMETHASONE DIPROPIONATE [ORANGE BOOK]
Common Name English
BECLOMETHASONE DIPROPIONATE [USP IMPURITY]
Common Name English
BELCHLORHINOL
Common Name English
VANCENASE AQ
Common Name English
NASOBEC
Common Name English
BECLOMETHASONE DIPROPIONATE [MI]
Common Name English
BECLOMETHASONE 17,21-DIPROPRIONATE
Common Name English
VENTOLAIR
Brand Name English
Beclometasone dipropionate [WHO-DD]
Common Name English
BETAMETHASONE DIPROPIONATE IMPURITY E
Common Name English
BECLOMETASONE DIPROPIONATE ANHYDROUS
Common Name English
BECONASE
Brand Name English
BECLOMETHASONE DIPROPIONATE [USP MONOGRAPH]
Common Name English
ORBEC
Common Name English
ENTYDERMA
Common Name English
SGX-202
Code English
SGX-201
Code English
BECLOVENT
Brand Name English
ORBESHIELD
Brand Name English
SCH-18020W
Code English
SANASTHMAX
Brand Name English
BECLOMETHASONE DIPROPIONATE [USAN]
Common Name English
TRIMBOW COMPONENT BECLOMETHASONE DIPROPIONATE
Common Name English
SANASTHYMYL
Common Name English
SCH 18020W
Code English
CLENIL A
Common Name English
BECLOMETASONE DIPROPIONATE, ANHYDROUS
EP  
Common Name English
BECLOMETASONI DIPROPIONAS [WHO-IP LATIN]
Common Name English
9-Chloro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
Common Name English
VANCENASE
Brand Name English
BECLOMETASONE DIPROPIONATE [EP MONOGRAPH]
Common Name English
BECLOMETHASONE 17,21-DIPROPIONATE
Common Name English
BECLOMETHASONE DIPROPIONATE [USP-RS]
Common Name English
SERNIVO
Brand Name English
VANCERIL
Brand Name English
BECLOMETASONE DIPROPIONATE [WHO-IP]
Common Name English
KORBUTONE
Common Name English
BECLOMET
Brand Name English
BECLOMETHASONE DIPROPIONATE [VANDF]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-CHLORO-11-HYDROXY-16-METHYL-17,21-BIS(1-OXOPROPOXY)-, (11.BETA.,16.BETA.)-
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 356311
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
FDA ORPHAN DRUG 111198
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
NCI_THESAURUS C521
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
FDA ORPHAN DRUG 146501
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
FDA ORPHAN DRUG 144201
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
FDA ORPHAN DRUG 285609
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
Code System Code Type Description
SMS_ID
100000091556
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
CHEBI
3002
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
RS_ITEM_NUM
1048506
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
FDA UNII
5B307S63B2
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
DRUG CENTRAL
294
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
BECLOMETHASONE DIPROPIONATE
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY Description: A white to creamy white powder; odourless. Solubility: Practically insoluble in water; soluble in 60 parts of ethanol (~750 g/l) TS. Category: Antiasthmatic drug. Storage: Beclometasone dipropionate should be kept in a well-closed container, protected from light. Definition: Beclometasone dipropionate contains not less than 96.0% and not more than 104.0% of C28H37ClO7, calculated with reference to the dried substance.
DRUG BANK
DB00394
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
EVMPD
SUB00681MIG
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
RXCUI
1348
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY RxNorm
IUPHAR
5894
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
DAILYMED
5B307S63B2
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
NSC
755901
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200500
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
ECHA (EC/EINECS)
226-886-0
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID3048730
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
WIKIPEDIA
BECLOMETASONE DIPROPIONATE
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
NCI_THESAURUS
C299
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
EVMPD
SUB26515
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
CAS
5534-09-8
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
PUBCHEM
21700
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY
MERCK INDEX
m2287
Created by admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
PRIMARY Merck Index
Related Record Type Details
TARGET -> AGONIST
DEGRADENT -> PARENT
SOLVATE->ANHYDROUS
TARGET -> AGONIST
Binds to the glucocorticoid receptor with about half the affinity of the potent glucocorticoid dexamethasone (Dexa), B was found to be 0·75 times less active than Dexa.
DEGRADENT -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MINOR
PLASMA
METABOLITE LESS ACTIVE -> PARENT
METABOLITE ACTIVE -> PRODRUG
MAJOR
PLASMA
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
http://apps.who.int/phint/pdf/b/Jb.6.1.43.pdf
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
17-BMP is about 13 times as potent as Dexa.
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC